Company news
In8bio, Inc. (NASDAQ:INAB) news
In8bio, Inc. news releases on 6ix. Latest, Oct 6, 2026: IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 6, 2026
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
September 9, 2026
IN8bio Reports Inducement Grant under Nasdaq Listing Rule 5635(4)
August 11, 2026
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 6, 2026
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
July 9, 2026
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
June 3, 2026
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
June 1, 2026
IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma
May 14, 2026
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 7, 2026
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
May 6, 2026
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2026
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
March 12, 2026
IN8bio to Present at TD Cowen 46th Annual Health Care Conference
February 24, 2026
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
February 9, 2026
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
February 3, 2026
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
January 12, 2026
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
December 19, 2025
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 6, 2025
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
October 29, 2025
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
October 27, 2025
IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 7, 2025
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
June 9, 2025
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
June 2, 2025
IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025
May 14, 2025
IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products
May 12, 2025
IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 7, 2025
IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences
April 29, 2025
IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025
April 28, 2025
IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025
March 31, 2025
IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025
March 18, 2025
IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
March 13, 2025
IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases
March 3, 2025
IN8bio to Present at the TD Cowen 45th Annual Health Care Conference
February 26, 2025
IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
February 24, 2025
IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients
February 10, 2025
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
December 9, 2024
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
November 24, 2024
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 11, 2024
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
November 11, 2024
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
November 4, 2024
IN8bio Announces Pricing of $12.4 Million Private Placement
September 30, 2024
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
September 3, 2024
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
August 11, 2024
IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 7, 2024
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
June 12, 2024
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
June 2, 2024
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
May 22, 2024
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
May 13, 2024
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
May 12, 2024